Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02986984 · ClinicalTrials.gov registry record

Transformative Research in Diabetic Nephropathy

A clinical trial of Diabetic Nephropathies and Diabetic Glomerulosclerosis, sponsored by University of Pennsylvania.

Recruiting
Registry status
400
Enrollment target
17
Study locations

NCT02986984: Recruiting study of Diabetic Nephropathies and Diabetic Glomerulosclerosis, sponsored by University of Pennsylvania.

NCT02986984 is a study of Diabetic Nephropathies and Diabetic Glomerulosclerosis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 400 participants, above the 94-participant average among 12 other Diabetic Nephropathies trials with a reported enrollment target (326% higher). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02986984, a study of Diabetic Nephropathies and Diabetic Glomerulosclerosis, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
400 participants
Enrollment target
17
Study locations

Study Summary

This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.

Primary Outcome

• Identification of epigenetic, genetic, renal, genomic, and biomarker profiles that differentiates patients with rapid GFR decline (\>5cc/min) from those with slower (\<5cc/min) rate of progression.

Conditions Studied

Diabetic Nephropathies Diabetic Glomerulosclerosis

Interventions

  • OTHER There is no intervention

Study Locations (17)

New York

  • Mount Sinai Hospital - New York
  • Columbia University - New York
  • Albert Einstein College of Medicine - The Bronx

California

  • University of Southern California - Los Angeles
  • Stanford University - Palo Alto

Pennsylvania

  • Lehigh Valley Health Network - Allentown
  • University of Pennsylvania - Philadelphia

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Connecticut

  • Yale University - New Haven

Illinois

  • Northwestern University - Chicago

Michigan

  • University of Michigan - Ann Arbor

New Mexico

  • University of New Mexico - Albuquerque

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2016-12
Est. Completion 2027-06
University of Pennsylvania

1,423 total trials

What NCT02986984 shows while recruiting

NCT02986984 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 94-participant average among 12 other Diabetic Nephropathies trials with a reported enrollment target (326% higher).

The record links to 2 conditions, with Diabetic Nephropathies appearing as the primary indexed condition, and to 1 intervention - of which There is no intervention is the first listed.

NCT02986984 lists 17 locations in 13 states (New York, California, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT02986984 about?

NCT02986984 is a clinical study titled "Transformative Research in Diabetic Nephropathy". This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and...

What is the current status of trial NCT02986984?

This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2016-12. Estimated completion is 2027-06.

What conditions does trial NCT02986984 study?

This clinical trial studies the following conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis.

What interventions are being tested in trial NCT02986984?

The interventions under investigation include: There is no intervention (OTHER).

Who is sponsoring clinical trial NCT02986984?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02986984 being conducted?

This trial has 17 study locations across Arkansas, California, Connecticut, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Nephropathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02986984's enrollment target sits among peer trials

400 1st of 12 higher than 12 of 12 other Diabetic Nephropathies trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Nephropathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT02986984

Source: ClinicalTrials.gov NCT02986984, the US trial registry maintained by the National Library of Medicine. NCT02986984 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.